Spacer
Spacer Home  |  Contact Us Spacer
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.
spacer
Banner for News pages
spacer
spacer

Conferences, Abstracts, and Publications

Gastroenterology Article
Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.
Lähdeaho ML, Kaukinen K, Laurila K, Vuotikka P, Koivurova OP, Kärjä-Lahdensuu T, Marcantonio A, Adelman DC, Mäki M.
Gastroenterology. 2014 Jun;146(7)

Digestive Disease Week (DDW) 2014
Poster:  Celiac Disease Patients Attempting Adherence To A Gluten-Free Diet Who Continue To Have Moderate Or Severe Symptoms Have Clinically Significant Mucosal Injury

Celiac Disease Center at Columbia University Development of Therapies for Celiac Disease Conference 2014
Oral Presentation

International Celiac Disease Symposium (ICDS) 2013
2 Oral Presentations
2 Posters

American College Gastroenterology Conference (ACG) 2012
Poster

Digestive Disease Week (DDW) 2012
2 Posters

Digestive Diseases and Sciences Article
Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials.
Siegel M, Garber ME, Spencer AG, Botwick W, Kumar P, Williams RN, Kozuka K, Shreeniwas R, Pratha V, Adelman DC.
Dig Dis Sci. 2012 Feb;57(2):440-50

United European Gastric Week (UEGW 2011)
Abstract and Oral Presentation

Digestive Disease Week (DDW) 2011
Poster

Digestive Disease Week (DDW) 2010
ALV003, a Mixture of Two Oral Proteases, Degrades Immunogenic Gluten Epitopes in a Complex Food Environment
Alvine DDW Poster

Clinical Immunology Article
The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo.
Tye-Din JA, Anderson RP, Ffrench RA, Brown GJ, Hodsman P, Siegel M, Botwick W, Shreeniwas R.
Clin Immunol. 2010 Mar;134(3):289-95

Digestive Disease Week (DDW) 2009
Abstract ALV003, a Combination Oral Protease, is Active, Safe and Tolerable in Healthy Volunteers and Subjects with Celiac Disease in Phase 1 Trials
Oral Presentation
United European Gastric Week (UEGW 2008)
Abstract and Oral Presentation

Digestive Disease Week (DDW) 2010
ALV003, a Mixture of Two Oral Proteases, Degrades Immunogenic Gluten Epitopes in a Complex Food Environment
Alvine DDW Poster

Clinical Immunology Article
The Effects of ALV003 Pre-Digestion of Gluten on Immune Response and Symptoms in Celiac Disease In Vivo
Tye-Din J. et al Clinical Immunology (2010) 134, 289-295

Digestive Disease Week (DDW) 2009
Abstract ALV003, a Combination Oral Protease, is Active, Safe and Tolerable in Healthy Volunteers and Subjects with Celiac Disease in Phase 1 Trials
Oral Presentation

United European Gastric Week (UEGW 2008)
Abstract and Oral Presentation


Back To Top
 

www.clinicaltrials.gov >>   

spacer
spacer

Location

Alvine Pharmaceuticals, Inc.
Headquarters
75 Shoreway Rd., Suite B
San Carlos, CA 94070
view all contact info >>

Business Inquiries

Kirk Essenmacher, M.D., M.B.A.
T: (650) 596-2434
E: email BD >>

Clinical Inquiries

E: email info@alvinepharma.com >>

spacer
spacer